ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 121

Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis

Emily Liebling1, Walter Faig 2, Nicholas Moore 1, Nahomy Ledesma Vicioso 3 and Melissa Lerman 4, 1Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 2Children's Hospital of Philadelphia, Philadelphia, 3Weill Cornell Medical College, New York, New York, 4Philadelphia, Pennsylvania

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: juvenile idiopathic arthritis (JIA), Uveitis

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: JIA – associated uveitis (JIA-U) accounts for 20-40% of childhood noninfectious uveitis and affects 10-20% of patients with JIA. Its chronic course is often painless and insidious, and early treatment is crucial to prevent ocular damage and blindness. Screening guidelines have been established to detect uveitis, but even after treatment, patients are at risk of recurrence1. It is not known whether children with JIA-U should be evaluated for active uveitis at the time of detected arthritis flare. This is the first large, systematic evaluation of arthritis activity as it temporally relates to uveitis activity within a well-defined time period over the JIA-U disease course.

Methods: This is a retrospective, single-center, longitudinal cohort study using medical record

data of patients with JIA-U. Uveitis and arthritis data were collected longitudinally from 7/2013 – 12/2019. Presence of uveitis was defined by Standardization of Uveitis Nomenclature2; arthritis activity was defined by presence of arthritis in >0 joints. Repeated measure logistic regression was used to evaluate for an association between uveitis activity within 45 days before and after any arthritis activity. Correction for individual variables was also performed.  

Results: Ninety eight patients with JIA-U were included; 96 (97.9%) had anterior uveitis and 59 (60.2%) were oligoarticular subtype. There were 2765 ophthalmology and rheumatology visits across the cohort. 40 (41%) patients had 137 visits with active uveitis within 45 days of any arthritis activity, yielding a positive temporal association between arthritis and uveitis activity, odds ratio (OR) 1.90 [95% confidence interval (CI): 1.43, 2.52; p< 0.0001]. The oligoarticular subtype had the strongest association, OR 1.50 [95% CI: 1.08-], 2.09; p=0.015]. Sex, ANA status, and HLA-B27 status did not significantly affect the association. Treatment with biologic and non-biologic DMARDs alone and in combination decreased the association between arthritis and uveitis activity, but the overall estimated correlation remained significant, OR 1.73 [95% CI: 1.31, 2.29; p< 0.0001].

Conclusion: In patients with JIA-U, there is a positive association between arthritis activity and uveitis activity within a 45-day period, that is strongest in the oligoarticular subtype. This suggests that joint or eye disease flare should prompt referral to the ophthalmologist or rheumatologist, respectively. Biologic and non-biologic DMARD mono- and dual therapy mitigates, but does not eliminate, this association.

1.         Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K, German Uveitis in Childhood Study G. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(6):1015-1019.

2.         Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516. 

Table 1. Patient demographics and disease characteristics.
*Number of patients with at least 1 visit on biologic DMARD (non_etanercept) alone, non_biologic DMARD alone, or both concurrently.

Table 2. Association between active uveitis within 45_days of active arthritis. Repeated measure logistic regression of the overall estimate of correlation followed by the association corrected for individual variables.
* Indicates statistical significance (p<0.05) of association overall and corrected for individual variables.
§ Includes polyarticular RF (+) and undifferentiated subtypes.


Disclosure: E. Liebling, None; W. Faig, None; N. Moore, None; N. Ledesma Vicioso, None; M. Lerman, Amgen, 1.

To cite this abstract in AMA style:

Liebling E, Faig W, Moore N, Ledesma Vicioso N, Lerman M. Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/evaluating-the-relationship-between-juvenile-idiopathic-arthritis-disease-activity-and-uveitis-activity-a-retrospective-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-the-relationship-between-juvenile-idiopathic-arthritis-disease-activity-and-uveitis-activity-a-retrospective-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology